Is Lantern Pharma Inc. (LTRN) a Buy, Sell, or Hold?
NASDAQ : LTRN
Lantern Pharma Inc.
$2.8 USD
$0.05 (1.82%)
- Volume
- 42.53K
- Average Volume
- 215.21K
- Market Capitalization
- $35.73M
- P/E Ratio
- -1.93
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $5.74
- Year Low
- $1.11
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.87
Company Overview
NASDAQ
Panna Sharma
Biotechnology
Healthcare
LTRN
16
US
USD
Liquidity Metrics
0.02
1.87
1.87
1.30
0.00
Sales & Valuation
-$
0.00
9.14
-2.37
-1.34
Profitability
-$1.57
-$17.12M
0.00%
0.00%
-198.35%
-220.29%
P/E Metrics
-1.93
-0.08
-0.08
Analyst Price Target & Rating
2/5
3 Analysts
%
Financial Health Scores
-20.09
1/9
$3.28M
$7.22M
$3.78M
-$15.91M
Key Metrics (TTM)
$30.23M
0.00
-1.90
1.87
-198.35%
-473.92%
-51.42%
-42.96%
-352239 days
Company Executives
| Name | Title |
|---|---|
| Peter L. Nara | Co-Founder & Advisor |
| Panna Sharma | President, Chief Executive Officer & Director |
| Kishor Gopaldas Bhatia | Chief Scientific Officer & Scientific Consultant |
| Marc C. Chamberlain | Chief Medical Officer of Starlight Therapeutics |
| David R. Margrave | Chief Financial Officer & Secretary |
Poll Results
No votes yet today — be the first to share your view!
About Lantern Pharma Inc. (NASDAQ:LTRN) Stock
Lantern Pharma Inc. is a clinical-stage biotechnology firm dedicated to revolutionizing drug development through the strategic application of artificial intelligence, machine learning, and comprehensive genomic data analysis. Their primary drug candidate, LP-100, is currently undergoing Phase II clinical trials, targeting metastatic, castration-resistant prostate cancer. The company is also advancing LP-300 as a potential combination therapy for non-small cell lung cancer adenocarcinoma, specifically in individuals who are non-smokers or have never smoked. Furthermore, their preclinical pipeline includes LP-184, an alkylating agent engineered to inflict DNA damage upon cancer cells that either overexpress specific biomarkers or exhibit mutations within their DNA repair pathways. Beyond the ... se, Lantern Pharma maintains an antibody-drug conjugate (ADC) program for diverse cancer treatments. Central to their operations is the RADR artificial intelligence platform, which synergizes molecular data through advanced big data analytics and machine learning capabilities. Established in 2013, the company operates from its headquarters in Dallas, Texas.
2026-08-03 08:00:00
Lantern Pharma Inc. (Nasdaq: LTRN), a clinical-stage AI-driven precision oncology company, today announced the formal creation of Open-Medicine AI (OMAI) and th
2026-08-03 07:30:00
DALLAS--(BUSINESS WIRE)--Open Medicine AI is launched as separate entity by Lantern Pharma.
2026-07-28 07:45:00
DALLAS--(BUSINESS WIRE)--EMA Phase 1b/2 Clinical Trial for LP-184.
2026-07-23 08:01:00
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using artificial intelligence and genomic data to develop targeted cancer therapies, today announced that the United States Patent and Trademark Office has issued a Notice of Allowance for U.S. Patent Application No. 17/230,821, titled "Methods for the Treatment of Solid Tumor Cancers Using Illudins and Biomarkers." The allowed claims cover methods of selecting and treating patients with ovar.
2026-07-08 07:30:00
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage, AI-driven precision oncology company, today announced the launch of ZetaOmics, the computational-biology module of its multi-agentic AI co-scientist platform, withZeta.ai. ZetaOmics introduces an autonomous “Computational Biologist” persona (agent) that performs real, end-to-end bioinformatics and multi-omic analysis — across any cancer type, and is purpose-built for the rare and pediatric cancers that have long been.
2026-06-02 09:00:00
Lantern Pharma Inc. (NASDAQ: LTRN), an AI-driven precision oncology company, today reported clinical data and updates in the form of a presentation from its on
2026-06-02 08:13:00
DALLAS--(BUSINESS WIRE)--Harmonic Presentation in form of 8K.
2026-05-19 08:00:00
Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage, AI-driven precision oncology company, today announced that it has received a successful response to its r
Frequently Asked Questions
-
What is the current Lantern Pharma Inc. (LTRN) stock price?
-
Lantern Pharma Inc.(NASDAQ:LTRN) stock price is $2.8 in the last trading session. During the trading session, LTRN stock reached the peak price of $5.744 while $1.11 was the lowest point it dropped to. The percentage change in LTRN stock occurred in the recent session was 1.82% while the dollar amount for the price change in LTRN stock was $0.05.
-
LTRN's industry and sector of operation?
-
The NASDAQ listed LTRN is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of LTRN?
-
Peter L. Nara | Co-Founder & Advisor
Panna Sharma | President, Chief Executive Officer & Director
Kishor Gopaldas Bhatia | Chief Scientific Officer & Scientific Consultant
Marc C. Chamberlain | Chief Medical Officer of Starlight Therapeutics
David R. Margrave | Chief Financial Officer & Secretary -
How many employees does LTRN have?
-
Number of LTRN employees currently stands at 16. LTRN operates from 1920 McKinney Avenue, Dallas, TX 75201, US.
-
Link for LTRN official website?
-
Official Website of LTRN is: https://www.lanternpharma.com
-
How do I contact LTRN?
-
LTRN could be contacted at phone #972 277 1136 and can also be accessed through its website. LTRN operates from 1920 McKinney Avenue, Dallas, TX 75201, US.
-
How many shares of LTRN are traded daily?
-
The average number of LTRN shares traded daily for last 3 months was 215.21K.
-
What is the market cap of LTRN currently?
-
The market value of LTRN currently stands at $35.73M with its latest stock price at $2.8